黑料网官网

Igene Co., Ltd. was established in June 2000 to engage in the business of developing new bio drugs. Since taking its first step, Igene Co., Ltd. has continued to research and develop biopharmaceuticals to overcome the decline in quality of life due to aging. Aijin鈥檚 core technologies are broadly divided into two categories. The ischemic disease treatment candidate (EGT022), a product of proteomics-based technology, is being developed as a treatment for diabetic retinopathy, bedsores, wounds, and myocardial ischemia and reperfusion damage, and is unique to Igene, established through immunology research. The development of various premium vaccines for adults using adjuvants is also being actively carried out. Ultimately, our business goal is to become a leader in the 21st century life science field and further improve the quality of life for humanity by establishing various new drugs, preventive vaccines, and diagnostic systems for the treatment and prevention of geriatric diseases.